ARENA PHARMACEUTICALS INC (ARNA) Stock Price & Overview
NASDAQ:ARNA
Current stock price
The current stock price of ARNA is 99.99 null. Today ARNA is up by 0.06%. In the past month the price increased by 7.01%. In the past year, price increased by 29.74%.
ARNA Key Statistics
- Market Cap
- 6.165B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -8.84
- Dividend Yield
- N/A
ARNA Stock Performance
ARNA Stock Chart
ARNA Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to ARNA. When comparing the yearly performance of all stocks, ARNA is one of the better performing stocks in the market, outperforming 98.23% of all stocks.
ARNA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ARNA. While ARNA seems to be doing ok healthwise, there are quite some concerns on its profitability.
ARNA Earnings
ARNA Forecast & Estimates
19 analysts have analysed ARNA and the average price target is 99.8 null. This implies a price decrease of -0.19% is expected in the next year compared to the current price of 99.99.
For the next year, analysts expect an EPS growth of 2.6% and a revenue growth 4629.54% for ARNA
ARNA Groups
Sector & Classification
ARNA Financial Highlights
Over the last trailing twelve months ARNA reported a non-GAAP Earnings per Share(EPS) of -8.84. The EPS decreased by -19.46% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -1141511.11% | ||
| ROA | -78.55% | ||
| ROE | N/A | ||
| Debt/Equity | 0.05 |
ARNA Ownership
ARNA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.93 | 369.265B | ||
| AMGN | AMGEN INC | 15.01 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.85 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.4 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.32 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.27 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 10.72 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.74 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.39 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ARNA
Company Profile
Arena Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel drugs that target G protien-coupled receptors. The company is headquartered in San Diego, California and currently employs 448 full-time employees. The company went IPO on 2000-07-28. The firm's clinical programs include Etrasimod, which is an oral, selective sphingosine 1-phosphate (S1P), receptor modulator, designed to provide systemic and local cell modulation by targeting S1P receptor subtypes one, four and five. Olorinab, an orally available, potent, peripherally acting, selective, full agonist of the CB2 receptor, is an internally discovered investigational drug candidate. APD418 is an adrenergic receptor (AdrR) antagonist and cardiac myotrope designed to regulate myofilament calcium sensitivity in order to improve contractility without inducing the adverse events associated with available inotropes. Temanogrel is a peripherally acting and selective 5HT2a inverse agonist designed to inhibit serotonin (5-HT) mediated amplification of platelet aggregation and vasoconstriction.
Company Info
IPO: 2000-07-28
ARENA PHARMACEUTICALS INC
6154 Nancy Ridge Dr
San Diego CALIFORNIA 92121 US
CEO: Amit D. Munshi
Employees: 448
Phone: 18584537200.0
ARENA PHARMACEUTICALS INC / ARNA FAQ
Can you describe the business of ARENA PHARMACEUTICALS INC?
Arena Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel drugs that target G protien-coupled receptors. The company is headquartered in San Diego, California and currently employs 448 full-time employees. The company went IPO on 2000-07-28. The firm's clinical programs include Etrasimod, which is an oral, selective sphingosine 1-phosphate (S1P), receptor modulator, designed to provide systemic and local cell modulation by targeting S1P receptor subtypes one, four and five. Olorinab, an orally available, potent, peripherally acting, selective, full agonist of the CB2 receptor, is an internally discovered investigational drug candidate. APD418 is an adrenergic receptor (AdrR) antagonist and cardiac myotrope designed to regulate myofilament calcium sensitivity in order to improve contractility without inducing the adverse events associated with available inotropes. Temanogrel is a peripherally acting and selective 5HT2a inverse agonist designed to inhibit serotonin (5-HT) mediated amplification of platelet aggregation and vasoconstriction.
What is the stock price of ARENA PHARMACEUTICALS INC today?
The current stock price of ARNA is 99.99 null. The price increased by 0.06% in the last trading session.
What is the dividend status of ARENA PHARMACEUTICALS INC?
ARNA does not pay a dividend.
What is the ChartMill rating of ARENA PHARMACEUTICALS INC stock?
ARNA has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the GICS sector and industry of ARNA stock?
ARENA PHARMACEUTICALS INC (ARNA) operates in the Health Care sector and the Biotechnology industry.
Can you provide the upcoming earnings date for ARENA PHARMACEUTICALS INC?
ARENA PHARMACEUTICALS INC (ARNA) will report earnings on 2022-05-03.